Loading…
Employees: 700
Size Cytek Biosciences (CTKB) is a United States Health Care company (Medical Specialties) with a market value of $758M, the 2430th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.83 on 6 Nov 2026.
Performance Over six months the shares gained 26.5%, against -10.0% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 5.4% over the last twelve months (peer median +14.1%); the operating margin is -21.6% (peer median 11.5%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 3.1× (9th cheapest of 21).
Capital Return on invested capital runs 47.5 points below its cost of capital (10.4% WACC).
Backlog Backlog (remaining performance obligations) was $49.0M at 30 Sep 2026, up 9% on a year earlier — 0.2 years of trailing revenue. Backlog detail →
Short interest Short interest is 3.4% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $207M | $201M | $200M | $193M | $164M |
| Revenue growth | — | +1% | +4% | +18% | — |
| Gross profit | $110M | $104M | $111M | $109M | $102M |
| EBITDA | -$32.7M | -$28.4M | -$12.6M | -$17.1M | $4.50M |
| Net income | -$80.6M | -$66.5M | -$6.02M | -$12.1M | $2.58M |
| Free cash flow | -$12.1M | -$8.77M | $21.9M | $633,000 | -$22.0M |
| Capital expenditure | $6.13M | $4.19M | $3.73M | $4.83M | $9.87M |
| Total debt | $35.2M | $33.0M | $27.8M | $33.2M | $35.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CTKB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.8% | -3.6% | 4th highest of 21 |
| 6-month return | +26.5% | -10.0% | 4th highest of 21 |
| Distance from 52-week high | -8.0% | -30.4% | highest of 21 |
| Revenue growth (TTM) | +5.4% | +14.1% | 8th lowest of 21 |
| Operating margin | -21.6% | 11.5% | 3rd lowest of 21 |
| EV / Sales | 2.6× | 3.1× | 9th cheapest of 21 |
| ROIC minus cost of capital | -47.5 pp | +2.4 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | 2.6× | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 3.3× | -2.4% | +15.7% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | 11.1× | 33.5% | -0.6% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 3.3× | 13.5% | +13.3% |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 0.7× | -10.5% | +12.4% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 2.8× | -2.1% | +11.8% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 2.0× | 0.1% | +15.6% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 1.4× | n/a | n/a |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 1.2× | n/a | n/a |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 4.1× | -2.1% | +23.5% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 1.6× | 11.1% | +14.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 3.7× | 16.7% | +25.9% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | 8.9× | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 0.9× | -8.0% | +6.6% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | 1.6× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 3.4× | 21.1% | +13.2% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 3.0× | 0.1% | +40.3% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 6.8× | 21.1% | +24.2% |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | 17.2× | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 2.5× | 9.2% | -10.2% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | 7.6× | n/a | n/a |
Cytek Biosciences reported $49.0M of remaining performance obligations at 30 Sep 2026, up 9% from a year earlier and up 4% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 1.03.